CALT
Calliditas Therapeutics AB - ADR

1,096
Loading...
Loading...
News
all
press releases
Delisting of Calliditas Therapeutics AB (publ) from Nasdaq Stockholm
Delisting of Calliditas Therapeutics AB (publ) from Nasdaq Stockholm Delisting of Calliditas Therapeutics AB (publ) from Nasdaq Stockholm PR Newswire STOCKHOLM, Sept. 16, 2024 STOCKHOLM, Sept. 16...
PR Newswire·1y ago
News Placeholder
More News
News Placeholder
Notice of extraordinary meeting of Calliditas Therapeutics AB (publ)
Notice of extraordinary meeting of Calliditas Therapeutics AB (publ) Notice of extraordinary meeting of Calliditas Therapeutics AB (publ) PR Newswire STOCKHOLM, Sept. 3, 2024 STOCKHOLM, Sept. 3, 2024...
PR Newswire·1y ago
News Placeholder
Calliditas Therapeutics takes certain corporate actions following announcement by Asahi Kasei
Calliditas Therapeutics takes certain corporate actions following announcement by Asahi Kasei Calliditas Therapeutics takes certain corporate actions following announcement by Asahi Kasei PR Newswire...
PR Newswire·1y ago
News Placeholder
Calliditas Interim Report January to June 2024
Calliditas Interim Report January to June 2024 Calliditas Interim Report January to June 2024 PR Newswire STOCKHOLM, Aug. 13, 2024 STOCKHOLM, Aug. 13, 2024 /PRNewswire/ -- Calliditas Therapeutics AB...
PR Newswire·1y ago
News Placeholder
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DRQ, LSAK, CALT on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DRQ, LSAK, CALT on Behalf of Shareholders SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DRQ, LSAK, CALT on Behalf of Shareholders...
PR Newswire·1y ago
News Placeholder
STOCKHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of the Merger and its Tender Offer, Expiring August 30, 2024, for shares of Calliditas Therapeutics AB - CALT
STOCKHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of the Merger and its Tender Offer, Expiring August 30, 2024, for shares of Calliditas Therapeutics AB - CALT STOCKHOLDER...
PR Newswire·1y ago
News Placeholder
Calliditas partner STADA receives European Commission decision for full approval of Kinpeygo for the treatment of IgA Nephropathy
Calliditas partner STADA receives European Commission decision for full approval of Kinpeygo for the treatment of IgA Nephropathy Calliditas partner STADA receives European Commission decision for...
PR Newswire·1y ago
News Placeholder
Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitis
Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitis Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitis PR Newswire...
PR Newswire·1y ago
News Placeholder
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALIM, DOMA, CALT on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALIM, DOMA, CALT on Behalf of Shareholders SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALIM, DOMA, CALT on Behalf of Shareholders...
PR Newswire·1y ago
News Placeholder
Launch of Phase 3 clinical trial with Nefecon in Japan
Launch of Phase 3 clinical trial with Nefecon in Japan Launch of Phase 3 clinical trial with Nefecon in Japan PR Newswire STOCKHOLM, July 4, 2024 STOCKHOLM, July 4, 2024 /PRNewswire/ -- Calliditas...
PR Newswire·1y ago

Latest CALT News

View

Advertisement. Remove ads.

Advertisement. Remove ads.